Supplementary information
MALIGNANCIES

Supplementary Materials for Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I studyThese authors contributed equally: Yi Que, Juan Wang, Feifei Sun, Shan Wang